Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on Cytek Biosciences (NASDAQ:CTKB) but lowered the price target from $8 to $7.
November 09, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Cytek Biosciences but lowered the price target from $8 to $7.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100